Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?Meihua Wang, Scot Ebbinghaus, Xiaoyun Li et al.|Journal for ImmunoTherapy of Cancer|2019Cited by 25
Overall Survival With Second-Line Pembrolizumab in Patients With Non–Small-Cell Lung Cancer: Randomized Phase III Clinical Trial Versus Propensity-Adjusted Real-World DataThomas Jemielita, Cong Chen, Xiaoyun Li et al.|JCO Clinical Cancer Informatics|2021Cited by 15
Augmenting Real-World Data Through Modeling Key Clinical Trial Eligibility Criteria: An Example of Patients With Non–small-Cell Lung Cancer Treated With PembrolizumabThomas Jemielita, Cong Chen, Kai‐Li Liaw et al.|JCO Clinical Cancer Informatics|2021Cited by 3
Additional file 3: of Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?Meihua Wang, Scot Ebbinghaus, Cong Chen et al.|Figshare|2019Cited by 0
Additional file 4: of Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?Meihua Wang, Scot Ebbinghaus, Cong Chen et al.|Figshare|2019Cited by 0